Bondi B, Kahaly GJ, Robertson RP (2019) Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev 40(3):789–824

Article  Google Scholar 

Okpara H, Ene A, Enang E, Aluka T (2017) Spectrum of thyroid dysfunction among patients evaluated by thyroid function tests at a tertiary clinical laboratory in Calabar, Nigeria. Annals Med Health Sci Res 7:411–417

Google Scholar 

Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM et al (2018) Global epidemiology of hyperthyroidism and hypothyroidism. Nat Reviews Endocrinol 14(5):301–316

Article  Google Scholar 

Crook M (2013) Clinical Biochemistry and Metabolic Medicine. CRC Press. pp.164-165 Hodder Arnold, an imprint of Hodder Education, Hodder and Stoughton Ltd, a division of HachetteUK, 338 Euston Road, London, NW1 3BH

Gabora K, Piciu A, Bădulescu IC, Larg MI, Stoian I-A, Piciu D (2019) Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors. Drug Metab Rev 51(4):562–569

Article  PubMed  Google Scholar 

Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758–3765

Article  PubMed  PubMed Central  Google Scholar 

Longo DL (2017) Imatinib changed everything. N Eng J Med 376:982–983

Article  Google Scholar 

De Groot JW, Zonnenberg BA, Van Ufford- Mannesse PQ, De Vries MM, Links TP, Lips CJM (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metabolism 92(9):3466–3469

Article  Google Scholar 

Ghalaut VS, Prakash G, Bala M, Bansal P, Dahiya K, Ghalaut PS et al (2013) Imatinib and thyroid dysfunction in BCR-ABL positive CML patients. Am J Cancer Therapy Pharmacol 1(1):1–7

Google Scholar 

Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U et al (2010) Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20(11):1209–1214

Article  PubMed  Google Scholar 

Abdel-Rahman O, Fouad M (2014) Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta-analysis. Expert Rev Anticancer Ther 14(9):1063–1073

Article  PubMed  Google Scholar 

Dey Anupam, Kanneganti V, Das D (2019) A study of the cardiac risk factors emerging out of subclinical hypothyroidism. J Family Med Prim care 8(7):2439–2444

Article  PubMed  Google Scholar 

Khaleel KJ (2016) Hematological events and thyroid status in Imatinib treated CML. Iraqi J Cancer Med Genet 8;9(2):133–136

De Groot JW, Zonnenberg BA, Plukker JT, Van Der Graaf WT, Links TP (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78(4):433–438

Article  PubMed  Google Scholar 

Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M et al (2013) Pitfalls in the measurement and interpretation of thyroid function tests. Best practice& Res Clin Endocrinol Metabolism 27(6):745–762

Article  Google Scholar 

De Carvalho GA, Perez CLS, Ward LS (2013) The clinical use of thyroid function tests. Arquivos Brasileiros De Endocrinologia Metabologia 57:193–204

Article  PubMed  Google Scholar 

Mathew A, Fuhrer D, Lahner H (2021) Sunitinib-induced hypothyroidism and survival in pancreatic neuroendocrine tumors. Horm Metabolic Res 53(12):794–800

Article  Google Scholar 

Sokal JE, Cox EB, Bacarrani M, Tura S, Gomez GA, Robertson JE (1984) Prognostic indication in ‘good-risk’ chronic granulocytic leukaemia. Blood 63(4):789–799

Article  PubMed  Google Scholar 

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. J Natl cancer inst 90:850–858

Article  PubMed  Google Scholar 

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686–692

Article  PubMed  Google Scholar 

Okafor EE, Ugonabo MC, Chuckwukelu EE, Okonkwo IN, Ezigbo E, Odurukwe O (2019) Prevalence and pattern of thyroid disorders among Patients Attending University of Nigeria Teaching Hospital, Enugu, Southeastern, Nigeria. Niger Med J 60(2):62–67

Article  PubMed  PubMed Central  Google Scholar 

Jimoh AK, Ghazal MS, Adeleke AB, Adeniyi AA, Adebara IO, Babalola FO et al (2020) Biochemical pattern of thyroid function test and clinical impression of thyroid disorder in a rural tertiary health institution in Nigeria. Ann Afr Med 19(2):89–94

Article  PubMed  PubMed Central  Google Scholar 

Boelaert K (2013) Thyroid dysfunction in the elderly. Nat Rev Endocrinol 9:194–204

Article  PubMed  Google Scholar 

Oyekunle AA, Durosinmi MA, Bolarinwa RA, Owojuyigbe T, Salawu L, Akinola NO (2016) Chronic myeloid leukemia in Nigerian patients: Anemia is an independent predictor of overall survival. Clin Med Insights: Blood Disorders 9:9–13

PubMed  PubMed Central  Google Scholar 

Vasi NB, Yorulmaz G, Garbioglu DB, Yildiz B, Dincer M (2023) Baseline serum TSH levels predict TheThyroid Dysfunction in Cancer patients treated with tyrosine kinase inhibitors and immunotherapy. Endocr Abstract 90:EP1168

Google Scholar